Next Article in Journal
Effects of Geomaterial-Originated Fillers on Microstructure and Mechanical/Physical Properties of α- and β-Chitosan-Based Films
Next Article in Special Issue
Sustainable Valorization of Tomato By-Products to Obtain Bioactive Compounds: Their Potential in Inflammation and Cancer Management
Previous Article in Journal
High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist
Previous Article in Special Issue
Anticancer Properties of Eugenol: A Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 24
10.3390/molecules26247512
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate

by
Yu-Yao Wu
†,
Yan-Ming Xu
† and
Andy T. Y. Lau
*
Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou 515041, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2021, 26(24), 7512; https://doi.org/10.3390/molecules26247512
Submission received: 31 October 2021 / Revised: 3 December 2021 / Accepted: 7 December 2021 / Published: 11 December 2021
(This article belongs to the Special Issue Preventive and Therapeutic Effects of Plant Bioactive Compounds in Chronic Inflammation and Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

:
Moringa oleifera (M. oleifera), which belongs to the Moringaceae family, is a common herb, rich in plant compounds. It has a variety of bioactive compounds that can act as antioxidants, antibiotics, anti-inflammatory and anti-cancer agents, etc., which can be obtained in different body parts of M. oleifera. Isothiocyanates (ITCs) from M. oleifera are one class of these active substances that can inhibit cancer proliferation and promote cancer cell apoptosis through multiple signaling pathways, thus curbing cancer migration and metastasis, at the same time they have little adverse effect on normal cells. There are multiple variants of ITCs in M. oleifera, but the predominant phytochemical is 4-(α-L-rhamnosyloxy)benzyl isothiocyanate, also known as moringa isothiocyanate (MIC-1). Studies have shown that MIC-1 has the possibility to be used clinically for the treatment of diabetes, neurologic diseases, obesity, ulcerative colitis, and several cancer types. In this review, we focus on the molecular mechanisms underlying the anti-cancer and anti-chronic disease effects of MIC-1, current trends, and future direction of MIC-1 based treatment strategies. This review combines the relevant literature of the past 10 years, in order to provide more comprehensive information of MIC-1 and to fully exploit its potentiality in the clinical settings.

1. Introduction

According to the latest survey released by the International Agency for Research on Cancer of the World Health Organization, the number of cancer deaths worldwide is rising [1], and the methods commonly used for cancer treatment are percutaneous ablation treatments, surgical resection, and chemotherapy [2,3,4]. Although these methods effectively improve the survival rate in cancer patients, the overall survival rate is still very low. The lack of effective treatment programs cause serious health problems that are necessary and urgent for early cancer patients. At present, medicinal plants have entered the vision of cancer researchers, which become an important source for drug development. Screening, extracting, and exploring new compounds from Chinese herbal medicine is an important way to develop efficient and low-toxicity anti-cancer drugs [5,6,7].
Moringa oleifera (M. oleifera) is a perennial tree, 3–13 m tall, native to India, due to its introduction to some countries, is widely planted in tropical areas, also cultivated in Taiwan and Guangdong of China (Figure 1) [8]. It is a tropical multifunctional tree with all parts of medical value for a variety of diseases, including fever, asthma, viral infection, cancer, etc. [9]. M. oleifera seeds are a very promising resource, due to their content of monounsaturated fatty acids and important bioactive compounds including alkaloids, glucosinolates (GLs), isothiocyanates (ITCs) and thiocarbamates [10]. They are commonly used in folk medicine to treat stomach pain, ulcers, poor vision, joint pain, and help digestion [9]. Studies show that the M. oleifera seed ingredients have the coagulant, bactericidal, fungicidal, and insecticidal properties [11] and administrating M. oleifera seeds powder can significantly protect animals from oxidative stress and reduce tissue arsenic concentration [12]. The leaves are the most used part of the plant, and the leaves of M. oleifera are rich in vitamins, carotenoids, polyphenols, phenolic acids, flavonoids, alkaloids, glucosine, isothiocyanate, tannins, and saponins [13]. Studies have demonstrated that M. oleifera leaves are beneficial for several chronic diseases, including hypercholesterolemia, hypertension, diabetes, insulin resistance, non-alcoholic liver disease, cancer, and overall inflammation [14]. While in the bark of the roots and stems, the protocyanogen protein is contained. Extracts from M. oleifera leaves, roots, stem, and bark all exhibit strong antioxidant activity in vitro [15]. M. oleifera flowers are high in protein, dietary fiber, and total phenols [16]. All of these make M. oleifera exhibiting properties including anti-proliferation, liver protection, anti-inflammation, anti-atherosclerosis, oxidative DNA damage protection, anti-peroxidation, and heart protection [17]. Current studies have shown the potential of M. oleifera as an anti-cancer drug, and research has found that its extract can inhibit cell proliferation, growth, and migration by affecting different signaling pathways in cells [18,19]. Similar to selenium (Se) in cancer prevention, M. oleifera extract is also able to promote cancer apoptosis through mitochondria, such as studies showing that M. oleifera extract has significant anti-cancer effects on melanoma cells in vitro involving mitochondria-mediated caspase enzyme-dependent and caspase enzyme-independent apoptotic pathways [20,21]. At the same time, M. oleifera has a great potential to inhibit tumor progression without affecting the normal physiology and function of the body, and therefore can be used as a cancer treatment drug.
ITCs are natural small molecules formed by glucosinolate precursors in cruciferous vegetables, which reduce the activation of carcinogens and increase the detoxification of carcinogens [22]. The ITCs formed by the biotransformation of M. oleifera GLs contain additional sugars in their chemical structures, which provide stability for these bioactive compounds compared to other ITCs found in other crops [23]. MIC-1 is one of ITCs, especially enriched in the seeds of the M. oleifera [24], and is so far the predominant phytochemical in M. oleifera seed extraction [25,26]. One of its most remarkable biological properties is its anti-inflammatory role [27]. Inflammation is a protective response of the body to a variety of internal or external stimuli derived from physical, chemical, or biological sources, including physical forces, radiation, extreme temperature, stimuli, pathogens, and metabolic overload, and increasing evidence suggests that chronic inflammation leads to cancer [28,29]. During chronic inflammation, activated macrophages are thought to cause continuously deteriorating inflammation through sustained and excessive production of inflammatory mediators such as cytokines, chemokines, lysozymes, proteases, growth factors, and eicosanes [30]. MIC-1 can cause the inability of activation of several transcription factors to inhibit the occurrence and development of inflammation [26]. This shows the anti-cancer potential of MIC-1.
This paper provides updates on MIC-1 from M. oleifera, combined the relevant literature for nearly 10 years, mainly from studying its anti-cancer property, in order to provide ideas for future tumor research and treatment.

2. Research Progress in M. oleifera

2.1. Bioactive Compounds from M. oleifera

Moringa is a valuable medicinal plant, different parts contain a variety of bioactive substances, and all parts of M. oleifera have medical value and can be overlapped to treat a variety of diseases [9]. Different parts of M. oleifera also contain different amounts of bioactive substances, carbohydrates is the most abundant in the roots and the least in the leaves [31]. Also the main material content varied with different treatments, with chlorogenic and gallic acids being the predominant phenolic acids in the raw leaf powder, while caffeic and gallic acids were higher in pretreated leaf powder [32]. Prabakaran et al. [33] determined five sites of M. oleifera by five different extraction methods and found that phenolics, flavonoids, myricetin, and quercetin had the highest content in leaves and gentisic acid and biochanin A were the highest in roots. At the same time, they also found that extraction of M. oleifera with ethyl acetate, ethanol, and methanol can obtain the maximum amount of potentially beneficial compounds in the extract and may contribute to the treatment of certain diseases. Except for the root, the content of glucomoringin was predominant in all body parts of M. oleifera [34]. Table 1 shows the major bioactive substances contained in different parts of M. oleifera.

2.2. M. oleifera: A Promising Anti-Cancer Agent

In anti-cancer studies, M. oleifera were found to slowdown the cancerous process through targeting chemoprevention, inhibiting carcinogen activation and inducing carcinogen detoxification, anti-inflammation, anti-proliferation of tumor cells, and inducing apoptosis of cancer cells [45,46].
While studying M. oleifera leaves, the researchers found that M. oleifera leaf extract could affect the growth of cancer cells through different signaling pathways. A study on human prostate cancer cell lines (PC-3), it was found that M. oleifera leaf extract controls PC-3 growth through three signaling pathways. After grinding the M. oleifera leaves into powder, being extracted with ethyl acetate at room temperature and then treating the obtained extract found that the M. oleifera extract was capable of down-regulating GLI1 transcription factor and SMO protein mRNA expression in Hedgehog signaling pathway, the signaling pathway plays an important role in cell proliferation and differentiation. Meanwhile, the extract can also induce reactive oxygen species (ROS) production, promoting apoptosis through the activation of caspase 3. There is concentration-dependent effect of cell cycle stagnation in G0/G1 [47]. The research by Luetragoon et al. [48] found that the extract of M. oleifera leaf can up-regulate cysteine, downregulate the anti-apoptotic factors, and induce apoptosis of cancer cells. Besides, studies by Tiloke et al. [49] found that M. oleifera leaf extract significantly increased lipid peroxidation, DNA damage, and γH2AX levels, while causing significant increases in caspase 9, caspase 3/7, Bax, Smac/diablo, and cleaved PARP-1, inducing apoptosis. Reducing the proliferation of cancer cells is a way to control cancer cell amplification, and M. oleifera leaf extract significantly reduces the levels of c-myc, p-Bcl2, and Hsp70 to induce cell cycle stagnation [50]. A study of human non-small-cell lung cancer cell line (A549) by Xie et al. [51] found that the alkaloid extract of M. oleifera significantly inhibited p-JAK2 and p-STAT3 and has dose-dependent effects, these results suggest that the M. oleifera leaf extract works by inhibiting the JAK2/STAT3 signaling pathway, it is closely related to the proliferation, angiogenesis, invasion, and migration of non-small-cell lung cancer, which induced the apoptosis and cell cycle block of A549 cells. In addition to the above signaling pathway, M. oleifera leaves can also affect the activity of cancer cells through other ways, such as apoptosis mediated by the caspase pathway found by Do et al. [52], they use methanol extract, hexane fraction, chloroform fraction, ethyl acetate fraction, and water-soluble fraction to expose human melanoma cells, found that the leaf extract of M. oleifera induced melanoma cells to participate in the caspase-dependent and caspase-independent apoptotic pathways mediated by mitochondrial ROS, and promote tumor cell apoptosis.
Abd-Rabou et al. [53] found that M. oleifera seed oil can induce apoptosis of Caco-2 and HCT116 cells of colorectal cancer by inducing mitochondrial dysfunction, while unaffecting normal cells. How mitochondria mediated apoptosis still requires further experimental verification. Studies have shown that the water extract obtained from M. oleifera is anti-proliferative and promoting apoptosis, but they have no effect on healthy peripheral blood monocytes. Moreover, it was found that the pro-apoptotic effect of water extract in M. oleifera seeds was correlated with a decrease in protein expression of B-cell lymphoma 2 (BCL2) and sirtuin-1, which are involved in the apoptosis process [54]. The oil–water extract of M. oleifera seeds appears to differentiate between regulating the proliferation and apoptosis of healthy and cancer cells, and this ability may be associated with the microRNA present in the extract [54]. It is also speculated by Potestà et al. [54] that microRNA in extract can differentiate between healthy cells and cancer cells, and regulate their proliferation and apoptosis, respectively. Through further studies, specific human apoptosis-related target genes for plant miRNA were identified by Potestà et al. [55]. They found seed water extracts can lead to a decrease in BCL2 protein expression in tumor cells and a reduced mitochondrial membrane potential, and both are associated with cell apoptosis. For two scientists studying breast cancer, Adebayo et al. [56] ground M. oleifera seeds into powder, extracted their plant chemicals with ethanol, and then treated breast cancer cells (MCF7), observing that the extract of M. oleifera seeds significantly inhibited the proliferation of the cell line. Elsayed et al. [57] also found seed essential oil from M. oleifera has potent cytotoxic activities against MCF7. However, its specific mechanism needs further research and determination.
With relatively limited cancer studies on other parts of M. oleifera, Patriota et al. [58] treating sarcoma 180-bearing mice with trypsin inhibitor from M. oleifera flower found that it can cause significant tumor weight loss (90.1–97.9%). Al-Asmari et al. [59] found that bark extracts showed significant anti-cancer properties for MDA-MB-231 and HCT-8 cancer cells and had significantly lower cell survival in both cell lines, while the number of apoptotic cells in cancer cell lines increased significantly. Besides, the extract effectively stops the cell cycle in G2/M phase. Vasanth et al. [60] used M. oleifera stem bark extract to develop anti-cancerous colloidal silver, allowing the substance to treat HeLa cells and find that it can induce HeLa apoptosis by the production of ROS. The results show that the bark extract of M. oleifera has anti-cancer activity and can be used to develop new drugs for breast cancer and colorectal cancer, but the specific mechanism of action needs to be further studied. At the same time Siddiqui et al. [61] found that extract of M. oleifera fruit can reduce the proliferation of HepG2 cells while significantly reducing cell viability through ROS-mediated apoptosis and activation of caspase 3 enzyme activity. Abundant natural phytochemical is a potential in cancer treatment and daily nutrients can be a treasure trove of anti-cancer drugs. It is widely accepted that nanotechnology could be a future direction in cancer treatment. The application of phytochemicals in combination with nanotechnology amplifies the therapeutic effect and provides a new way to solve the difficult economic and environmental problems of nanotechnology. Therefore, combining phytochemicals with nanotechnology is a promising approach. However, challenges of nanotechnology are not yet fully settled. One of challenges in drug delivery is the safety for human health, as nanomaterial may not have immediate impact quickly. Furthermore, the manufacturing of nanomedicine products for commercialization is a key obstacle, as large-scale production is technically challenging and their physicochemical properties may vary from batch to batch. Though there has been great progress in the application of nanophytochemicals in the treatment of cancer, we have a long way to large-scale application of nanoparticles for drug delivery and many questions remain.

3. The Introduction of Isothiocyanates

3.1. Basic Information of Isothiocyanates

ITCs, sulfur-containing bioactive compounds [62] resulting from enzymatic hydrolysis of GLs [63], appear in many Brassicaceae vegetables [64] with a variety of biological functions, including antibacterial [65], antioxidant, anti-inflammation [66], anti-cancer [67], and other properties [68]. Clinical trials employing two ITCs, sulforaphane (SFN; 1-isothiocyanato-4-(methylsulfinyl)butane) and phenethyl isothiocyanate (PEITC; 2-isothiocyanatoethylbenzene) to treat various diseases from cancer to autism [69]. More than 100 ITCs have been reported in a variety of plants, and ITCs often present in the diet and have anti-tumor effects mainly include allyl-isothiocyanate (AITC), benzylisothiocyanate (BITC), PEITC, and SFN [70]. ITCs can permanently bind some important biomolecules, such as cytoskeletal proteins, transcription factors, as well as heat shock proteins, while they also inhibit histone deacetylases, affecting the epigenetic regulation of gene expression [71].
ITCs, which are contained in the M. oleifera body [24], are formed by the glycosylated precursor GLs via myrosinase (thioglucoside glucohydrolase), which is an enzyme activated during plant tissue damage or digestion. Myrosinase cleaves thio-linked glucose in GLs, leaving a rapid rearrangement to form four active and stable ITCs [72]. Among them, 4-(α-L-rhamnosyloxy)benzyl isothiocyanate and 4-(4′-O-acetyl-α-L-rhamnosyloxy)benzyl isothiocyanate are the most abundant ITCs formed by GLs, usually accounting for more than 95% of the total ITCs. 4-(2′-O-acetyl-α-L-rhamnosyloxy)benzyl isothiocyanate and 4-(3′-O-acetyl-α-L-rhamnosyloxy)benzyl isothiocyanate are only formed from microscopic amount of GLs precursors [73]. The structures of these ITCs are shown in Figure 2. Among them, 4- (α-L-rhamnosyloxy)benzyl isothiocyanate also known as MIC-1, ITC-1, RBITC, and GMG-ITC. Huang et al. [37] extracted 200 g of seeds with MeOH/H2O and purified 230 mg of 4- (α-L-rhamnosyloxy)benzyl isothiocyanate.

3.2. The Extraction Methods of MIC-1 from M. oleifera

ITCs are contained in all parts of the M. oleifera body, but it is higher in M. oleifera seeds than in any other tissue [24]. GLs and ITCs are usually extracted with methanol or ethanol, and the specific manner as well as the extraction effect, are described by Lopez-Rodriguez et al. [23]. At present, the more mature extraction methods of MIC-1 in M. oleifera is established by Jaja-Chimedza et al. [74] and Brunelli et al. [75], other researchers obtained the experimental materials needed in their own experiments by subtly adjusting some steps in these two methods. The resulting MIC-1 produced a significant anti-cancer, antioxidant, and anti-inflammation activity (Table 2). In addition, some researchers have explored the way MIC-1 is extracted in M. oleifera and conducted relevant studies, as shown in Table 2.

4. In Vivo and In Vitro Studies of MIC-1 from M. oleifera

ITCs present in M. oleifera are a class of substances with multiple biological activities. Many researchers have designed a series of experiments to study their specific biological functions, in order to provide ideas for future relevant clinical trials. Treatment of mice with different concentrations of ITCs revealed that ITCs mainly involving abnormal changes in the digestive (gastrointestinal tract, liver), immune (thymus, spleen, WBC, lymphocytes) and (male) reproductive systems (testicular germinal cells, epididymides) at higher concentrations. It is also speculated from these results that MIC-1 appears to be less toxic than other ITCs [91].

4.1. Anti-Cancer

MIC-1 was found to have the ability to inhibit cancer cell proliferation, promote apoptosis of cancer cells, and inhibit metastasis. At the same time, after treatment with MIC-1 for HepG2, Caco-2, and HEK293, cell viability determination using MTT revealed that MIC-1 exhibited selective cytotoxic and apoptotic activity in human and non-cancer cells [92]. Besides, MIC-1 can downregulate some signaling pathways associated with cancer cell proliferation to inhibit the development of cancer cells [93].

4.1.1. Neuroblastoma

Neuroblastoma (NBL) is the third-most common childhood malignancy following leukemia and brain tumors [94], and it is also the most common cancer type used to study the anti-cancer mechanism of MIC-1. Using SH-SY5Y human NBL cell line, researchers found that MIC-1 can inhibit the proliferation of malignant cell lines by activating apoptosis or programmed cell death. The phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) pathway is one of the most potent pro-survival pathways involved in the progression of NBL and is also associated with a poor prognosis [95,96]. Giacoppo, et al. [97] found that MIC-1 complexed with α-cyclodextrin can downregulate the levels of p-PI3K, p-Akt, and p-mTOR associated with this signaling pathway, thereby downregulating the signaling pathway and inhibiting SH-SY5Y cell survival. At the same time, MIC-1 can also inhibit the mitogen-activated protein kinase (MAPK) pathway, triggered by PI3K/Akt/mTOR signaling, which plays a key role in regulating many cellular functions, including survival, proliferation, and apoptosis in different cell types. In addition, MIC-1 can also upregulate p53 and p21 expression and promote caspase 3 cleavage, thus promoting apoptosis in SH-SY5Y cells. The study by Cirmi et al. [85] shown that MIC-1 can alter the normal progression of cells during the cell cycle, increase the number of cells in the G2 and S phases, reduce the number of cells in the G1 phase, and inhibit the nuclear translocation of NF-κB. Moreover, Jaafaru et al. [86] further found that MIC-1, even with oxidative damage by hydrogen peroxide, was able to preserve the membrane and internal structural integrity of differentiated neurons, suggesting its ability to protect neurons from oxidative stress degeneration. Thus it can be seen, targeting NBL deserves expansion to gain more evidence of how the compound provides these effects and promotes apoptosis, and the actual regulatory mechanistic pathways involved in the process.

4.1.2. Astrocytomas

Astrocytomas are the most aggressive primary brain tumor, and are also the most common and malignant primary brain tumors in adults [98]. Human astrocytoma grade IV CCF-STTG1 cells by Rajan et al. [87] found that MIC-1 effectively induced apoptosis through activation of p53 and Bax as well as inhibition of Bcl-2. At the same time, it can also induce oxidative stress-mediated apoptosis by modulating the expression of the oxidative stress-associated Nrf2 transcription factor and its upstream regulator casein kinase 2 alpha. Specific signaling pathways that regulate apoptosis require further investigation.

4.1.3. Hepatocarcinoma

Apoptosis is controlled by two pathways: the extrinsic pathway is activated by death ligands and their death receptor interactions, resulting in activation of initiator caspase 8 and effector caspase 3, and the intrinsic pathway regulated by initiator caspases 2 and 9, which in turn, activate effector caspase 3 [99]. Using MIC-1 and avenanthramide 2f (AVN 2f) to treat Hep3B hepatocarcinoma cells, Antonini et al. [100] found that MIC-1 and AVN 2f cocktail significantly inhibited the proliferation of Hep3B by increasing caspases 2, 8, 9, and 3 activity. Extrinsic apoptosis is apoptosis induced by AVN 2f -mediated activation of caspase 8, while the intrinsic apoptosis pathway is triggered by MIC-1-induced increased intracellular ROS levels, MIC-1-mediated activation of caspases 2 and 9, and MIC-1-mediated downregulation of the pro-survival gene BIRC5. The results suggest that the combination of MIC-1+AVN 2f may be an effective chemoprophylaxis cocktail against the development of liver cancer.

4.1.4. Skin Carcinoma

TPA is an accelerator of cancer development and induces inflammation, oxidative imbalance, and excessive cell proliferation. It can also promote the development of skin cancer [101]. Wang et al. [102] studied mouse epidermal JB6 cells induced by the tumor promoter TPA, found that MIC-1 treatment could alter gene expression changes induced by TPA. Seventy-six pathways activated by TPA, were inhibited by MIC-1; and nine signaling pathways inhibited by TPA, were activated by MIC-1. While most of these signaling pathways are inflammatory responses, cancer, and oxidative stress-related pathways such as involvement in NF-κB signaling, IL-1 signaling, LPS/IL-1-mediated inhibition of RXR function, PTEN signaling, p53 signaling, and Nrf2-mediated oxidative stress responses. At the same time, MIC-1 can also affect the methylation of the gene through epigenetic modifications, which reduces CpG methylation in the promoter region more greatly than that in other regions. Thus, it appears that MIC-1 is chemoprophylactic on TPA-induced tumor/tumorigenic transformation in mouse epidermal JB6 cells, while MIC-1 can also relieve inflammation and oxidative stress induced by TPA. A potential set of transcriptome and epigenomic biomarkers was observed in the course of the study by Wang et al. These findings provide new insights into how epigenetic modifications affect the progression of skin carcinogenesis and the prophylactic role of MIC-1.
Thus, it is seen that MIC-1 not only inhibits the development of cancer by inhibiting inflammation and proliferation related factors, but also promotes the expression of genes related to apoptosis. However, relevant animal and clinical trials are lacking in the study, and the cancer cell types involved need to be further extended. Figure 3 shows the signaling pathways involved in MIC-1 regulation in cancer cells as well as the expression of related genes. At the same time, there was the finding that MIC-1 degrades rapidly to several water-soluble products via a pseudo-first-order kinetics, in a recent study by Lu et al. [103]. Therefore, although MIC-1 is highly cytotoxic for cancer cells, its degradation product is very weak or even without such activity, suggesting that other isothiocyanate components in ITCs are also important for their cancer chemoprevention.

4.2. Anti-Inflammation

A large number of studies in recent years have reported on the anti-inflammatory effects of ITCs. Lipopolysaccharide (LPS) is a powerful inducer of inflammation, endotoxemia, and sepsis in cells and animals [104]. In an LPS mouse model, it was found that oral administration of chemically stable MIC-1 (80 mg/kg) significantly reduced the expression of inflammatory markers in liver, kidney, spleen, and colon and reduced spleen weight. Meanwhile, it can also activate Nrf2 and inhibit NF-κB signaling, reduce ROS in the cytosol, enabling reduced mitochondrial peroxide content and restoration of mitochondrial membrane potential [105]. NO is an important inflammatory mediator produced by nitric oxide synthase, and MIC-1 treatment can also reduce NO production [74]. The results from the studies suggest the possible link between MIC-1 and anti-inflammation.

4.3. Anti-Chronic Diseases

4.3.1. Anti-Diabetic

It is known that ulcerative colitis (UC) is an inflammatory bowel disease (IBD), a chronic intestinal disease characterized by recurrent inflammation in the gastrointestinal tract. Drug interventions are one of the key approaches for UC treatment. Using dextran sulfate sodium-induced acute UC mouse model, Kim et al. [106] found that MIC-1 decreases the secretion of colonic pro-inflammatory biomarkers and fecal lipocalin-2 levels, downregulates the colonic expression of pro-inflammatory cytokines and iNOS, and elevates the colonic expression of tight-junction proteins and Nrf2-mediated phase II detoxifying enzymes. MIC-1 improves the pathological events associated with acute and chronic UC, and the anti-inflammatory and antioxidant activity of MIC-1 may be related to Nrf2-mediated anti-inflammatory/antioxidant signaling. This study supports the therapeutic potential for MIC-1 prevention and treatment of UC, but should be further explored in human studies. ITCs also affects the onset of diabetes. Waterman, et al. [77] using MIC-1 to treat Type-2 diabetes mellitus (T2DM) rats, found that MIC-1 can delay the onset of diabetes in the T2DM rat model to a greater extent than moderate caloric restriction and it did not affect body weight or food intake.

4.3.2. Anti-Obesity

Jaja-Chimedza et al. [25] suggested that the extraction of M. oleifera seeds significantly improved metabolic health in diet-induced obesity and insulin-resistant mice, most likely to be an antimicrobial effect of MIC-1. MIC-1 inhibits the gut microbiome, which may reduce metabolic endotoxemia and improve overall metabolic health. At the same time, in vitro studies found that MIC-1 can indeed downregulate genes associated with obesity, further confirming the efficacy with MIC-1 [76]. These results support its documented traditional uses and a bioactive role of MIC-1 and suggest the potential efficacy for M. oleifera supplementation for diabetes management in populations.

4.3.3. Anti-MS

Multiple sclerosis (MS) is a chronic inflammatory disease, attacking the central nervous system, leads to demyelination, oligodendrocyte loss, glial scar formation, and subsequent degeneration of axonal and neuronal damage [107]. After treating the C57Bl/6 male mice with MIC-1, Galuppo et al. [108] found that GMG-ITC treatment is able to alleviate the inflammatory cascade behind the processes leading to severe MS. This suggests that the compound can be useful as a drug for the treatment or prevention of MS.
At the same time, researchers also found that MIC-1 can relieve neurologic pain by inhibiting inflammatory pathways and blocking voltage-gated ion channels in murine model of MS. These show that ITCs in M. oleifera, used clinically in the treatment of diseases, have great possibilities. However, the specific mechanisms involved, and the relevant precautions, also need to be determined through more clinical trials.

5. Conclusions

In conclusion, MIC-1 in M. oleifera has high safety and good physiological pharmacological activity and the cellular inhibitory effect of M. oleifera flowers, leaves, seeds, fruit, and bark shown in recent studies reflects the possibility of M. oleifera as a potential source of solutions to the current challenges faced in treating cancer. The soluble extract has a highly significant antitumor activity, likely due to the synergy of MIC-1 with other effective compounds in the extract that may enhance its activity. However, in-depth studies at the cellular and molecular levels are critical to address the limitations currently present. According to research findings that M. oleifera has a significant inhibitory effect on human lung, breast, prostate, pancreatic, and colorectal cancer cells, further well-designed in vivo studies should be conducted in order to provide more comprehensive information of M. oleifera and to fully exploit its potentiality in the clinical settings.

Author Contributions

Writing—original draft preparation, Y.-Y.W., Y.-M.X. and A.T.Y.L.; writing-review & editing, Y.-Y.W., Y.-M.X. and A.T.Y.L.; supervision, A.T.Y.L. and Y.-M.X.; funding acquisition, A.T.Y.L. and Y.-M.X. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the grants from the National Natural Science Foundation of China (Nos. 31771582 and 31271445), the Guangdong Natural Science Foundation of China (No. 2017A030313131), the “Thousand, Hundred, and Ten” Project of the Department of Education of Guangdong Province of China, the Basic and Applied Research Major Projects of Guangdong Province of China (2017KZDXM035 and 2018KZDXM036), the “Yang Fan” Project of Guangdong Province of China (Andy T. Y. Lau-2016; Yan-Ming Xu-2015), and the Shantou Medical Health Science and Technology Plan (200624165260857).

Acknowledgments

We would like to thank members of the Lau and Xu laboratory for critical reading of this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AITCAllyl-isothiocyanate
BCL2B-cell lymphoma 2
BITCBenzylisothiocyanate
COX-2Cyclooxygenase-2
GLsGlucosinolates
IBDInflammatory bowel disease
iNOSInducible nitric oxide synthase
ITCsIsothiocyanates
LPSLipopolysaccharide
MAPKMitogen-activated protein kinase
MSMultiple sclerosis
MSEM. oleifera seeds extraction
NBLNeuroblastoma
NF-κBNuclear factor-kappa B
NONitric oxide
PEITCPhenethyl isothiocyanate
ROSReactive oxygen species
SeSelenium
STATSignal transducer and activator of transcription
T2DMType-2 diabetes mellitus
UCUlcerative colitis

References

  1. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016, 7, 418–419. [Google Scholar] [CrossRef] [Green Version]
  2. Yasui, H. Safe Handling of Cancer Chemotherapy Drugs. Gan Kagaku Ryoho Cancer Chemother. 2016, 43, 503–508. [Google Scholar]
  3. Vogl, T.J.; Nour-Eldin, N.A.; Albrecht, M.H.; Kaltenbach, B.; Hohenforst-Schmidt, W.; Lin, H.; Panahi, B.; Eichler, K.; Gruber-Rouh, T.; Roman, A. Thermal Ablation of Lung Tumors: Focus on Microwave Ablation. RoFo: Fortschr. Auf Dem Geb. Der Rontgenstrahlen Und Der Nukl. 2017, 189, 828–843. [Google Scholar] [CrossRef] [Green Version]
  4. Wei, W.I.; Chan, J.Y.W. Surgical Treatment of Advanced Staged Hypopharyngeal Cancer. Adv. Oto-Rhino-Laryngol. 2019, 83, 66–75. [Google Scholar] [CrossRef]
  5. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F.H. Regulation of microRNAs by natural agents: An emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27, 1027–1041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Hu, Y.; Wang, S.; Wu, X.; Zhang, J.; Chen, R.; Chen, M.; Wang, Y. Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J. Ethnopharmacol. 2013, 149, 601–612. [Google Scholar] [CrossRef] [PubMed]
  7. Tang, X.; Liu, C.; Li, T.; Lin, C.; Hao, Z.; Zhang, H.; Zhao, G.; Chen, Y.; Guo, A.; Hu, C. Gambogic acid alleviates inflammation and apoptosis and protects the blood-milk barrier in mastitis induced by LPS. Int. Immunopharmacol. 2020, 86, 106697. [Google Scholar] [CrossRef] [PubMed]
  8. Committee of Chinese Botany of CAS. Chinese Botany; Science Press: Beijing, China, 1984; Volume 34(1), p. 6. [Google Scholar]
  9. Popoola, J.O.; Obembe, O.O. Local knowledge, use pattern and geographical distribution of Moringa oleifera Lam. (Moringaceae) in Nigeria. J. Ethnopharmacol. 2013, 150, 682–691. [Google Scholar] [CrossRef]
  10. Leone, A.; Spada, A.; Battezzati, A.; Schiraldi, A.; Aristil, J.; Bertoli, S. Moringa oleifera Seeds and Oil: Characteristics and Uses for Human Health. Int. J. Mol. Sci. 2016, 17, 2141. [Google Scholar] [CrossRef] [Green Version]
  11. Garcia, T.B.; Soares, A.A.; Costa, J.H.; Costa, H.P.S.; Neto, J.X.S.; Rocha-Bezerra, L.C.B.; Silva, F.D.A.; Arantes, M.R.; Sousa, D.O.B.; Vasconcelos, I.M.; et al. Gene expression and spatiotemporal localization of antifungal chitin-binding proteins during Moringa oleifera seed development and germination. Planta 2019, 249, 1503–1519. [Google Scholar] [CrossRef]
  12. Gupta, R.; Dubey, D.K.; Kannan, G.M.; Flora, S.J. Concomitant administration of Moringa oleifera seed powder in the remediation of arsenic-induced oxidative stress in mouse. Cell Biol. Int. 2007, 31, 44–56. [Google Scholar] [CrossRef] [PubMed]
  13. Leone, A.; Spada, A.; Battezzati, A.; Schiraldi, A.; Aristil, J.; Bertoli, S. Cultivation, Genetic, Ethnopharmacology, Phytochemistry and Pharmacology of Moringa oleifera Leaves: An Overview. Int. J. Mol. Sci. 2015, 16, 12791–12835. [Google Scholar] [CrossRef] [PubMed]
  14. Vergara-Jimenez, M.; Almatrafi, M.M.; Fernandez, M.L. Bioactive Components in Moringa oleifera Leaves Protect against Chronic Disease. Antioxidants 2017, 6, 91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Atawodi, S.E.; Atawodi, J.C.; Idakwo, G.A.; Pfundstein, B.; Haubner, R.; Wurtele, G.; Bartsch, H.; Owen, R.W. Evaluation of the polyphenol content and antioxidant properties of methanol extracts of the leaves, stem, and root barks of Moringa oleifera Lam. J. Med. Food 2010, 13, 710–716. [Google Scholar] [CrossRef] [PubMed]
  16. Madane, P.; Das, A.K.; Pateiro, M.; Nanda, P.K.; Bandyopadhyay, S.; Jagtap, P.; Barba, F.J.; Shewalkar, A.; Maity, B.; Lorenzo, J.M. Drumstick (Moringa oleifera) Flower as an Antioxidant Dietary Fibre in Chicken Meat Nuggets. Foods 2019, 8, 307. [Google Scholar] [CrossRef] [Green Version]
  17. Saini, R.K.; Sivanesan, I.; Keum, Y.S. Phytochemicals of Moringa oleifera: A review of their nutritional, therapeutic and industrial significance. 3 Biotech 2016, 6, 203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Berkovich, L.; Earon, G.; Ron, I.; Rimmon, A.; Vexler, A.; Lev-Ari, S. Moringa oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells. BMC Complementary Altern. Med. 2013, 13, 212. [Google Scholar] [CrossRef] [Green Version]
  19. Xie, J.; Luo, F.X.; Shi, C.Y.; Jiang, W.W.; Qian, Y.Y.; Yang, M.R.; Song, S.; Dai, T.Y.; Peng, L.; Gao, X.Y.; et al. Moringa oleifera Alkaloids Inhibited PC3 Cells Growth and Migration Through the COX-2 Mediated Wnt/β-Catenin Signaling Pathway. Front. Pharmacol. 2020, 11, 523962. [Google Scholar] [CrossRef]
  20. Do, B.H.; Hoang, N.S.; Nguyen, T.P.T.; Ho, N.Q.C.; Le, T.L.; Doan, C.C. Phenolic Extraction of Moringa oleifera Leaves Induces Caspase-Dependent and Caspase-Independent Apoptosis through the Generation of Reactive Oxygen Species and the Activation of Intrinsic Mitochondrial Pathway in Human Melanoma Cells. Nutr. Cancer 2021, 73, 869–888. [Google Scholar] [CrossRef]
  21. Tan, H.W.; Mo, H.Y.; Lau, A.T.Y.; Xu, Y.M. Selenium Species: Current Status and Potentials in Cancer Prevention and Therapy. Int. J. Mol. Sci. 2018, 20, 75. [Google Scholar] [CrossRef] [Green Version]
  22. Wu, X.; Zhou, Q.H.; Xu, K. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol. Sin. 2009, 30, 501–512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Lopez-Rodriguez, N.A.; Gaytán-Martínez, M.; de la Luz Reyes-Vega, M.; Loarca-Piña, G. Glucosinolates and Isothiocyanates from Moringa oleifera: Chemical and Biological Approaches. Plant Foods Hum. Nutr. 2020, 75, 447–457. [Google Scholar] [CrossRef]
  24. Wang, X.; Liu, Y.; Liu, X.; Lin, Y.; Zheng, X.; Lu, Y. Hydrogen Sulfide (H2S) Releasing Capacity of Isothiocyanates from Moringa oleifera Lam. Molecules 2018, 23, 2809. [Google Scholar] [CrossRef] [Green Version]
  25. Jaja-Chimedza, A.; Zhang, L.; Wolff, K.; Graf, B.L.; Kuhn, P.; Moskal, K.; Carmouche, R.; Newman, S.; Salbaum, J.M.; Raskin, I. A dietary isothiocyanate-enriched moringa (Moringa oleifera) seed extract improves glucose tolerance in a high-fat-diet mouse model and modulates the gut microbiome. J. Funct. Foods 2018, 47, 376–385. [Google Scholar] [CrossRef] [PubMed]
  26. Park, E.J.; Cheenpracha, S.; Chang, L.C.; Kondratyuk, T.P.; Pezzuto, J.M. Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression by 4-[(2’-O-acetyl-α-L-rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutr. Cancer 2011, 63, 971–982. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Lu, Y.; Wang, X.; Pu, H.; Lin, Y.; Li, D.; Liu, S.Q.; Huang, D. Moringin and Its Structural Analogues as Slow H(2)S Donors: Their Mechanisms and Bioactivity. J. Agric. Food Chem. 2020, 68, 7235–7245. [Google Scholar] [CrossRef]
  28. Cheenpracha, S.; Park, E.J.; Rostama, B.; Pezzuto, J.M.; Chang, L.C. Inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells by the norsesterterpene peroxide, epimuqubilin A. Mar. Drugs 2010, 8, 429–437. [Google Scholar] [CrossRef]
  29. Bower, J.E. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 2014, 11, 597–609. [Google Scholar] [CrossRef]
  30. Chen, P.; Bonaldo, P. Role of macrophage polarization in tumor angiogenesis and vessel normalization: Implications for new anticancer therapies. Int. Rev. Cell Mol. Biol. 2013, 301, 1–35. [Google Scholar] [CrossRef]
  31. Saucedo-Pompa, S.; Torres-Castillo, J.A.; Castro-López, C.; Rojas, R.; Sánchez-Alejo, E.J.; Ngangyo-Heya, M.; Martínez-Ávila, G.C.G. Moringa plants: Bioactive compounds and promising applications in food products. Food Res. Int. 2018, 111, 438–450. [Google Scholar] [CrossRef]
  32. Devisetti, R.; Sreerama, Y.N.; Bhattacharya, S. Processing effects on bioactive components and functional properties of moringa leaves: Development of a snack and quality evaluation. J. Food Sci. Technol. 2016, 53, 649–657. [Google Scholar] [CrossRef] [Green Version]
  33. Prabakaran, M.; Kim, S.-H.; Sasireka, A.; Chandrasekaran, M.; Chung, I.-M. Polyphenol composition and antimicrobial activity of various solvent extracts from different plant parts of Moringa oleifera. Food Biosci. 2018, 26, 23–29. [Google Scholar] [CrossRef]
  34. Amaglo, N.K.; Bennett, R.N.; Lo Curto, R.B.; Rosa, E.A.S.; Lo Turco, V.; Giuffrida, A.; Curto, A.L.; Crea, F.; Timpo, G.M. Profiling selected phytochemicals and nutrients in different tissues of the multipurpose tree Moringa oleifera L., grown in Ghana. Food Chem. 2010, 122, 1047–1054. [Google Scholar] [CrossRef]
  35. Huang, Q.; Liu, R.; Liu, J.; Huang, Q.; Liu, S.; Jiang, Y. Integrated Network Pharmacology Analysis and Experimental Validation to Reveal the Mechanism of Anti-Insulin Resistance Effects of Moringa oleifera Seeds. Drug Des. Dev. Ther. 2020, 14, 4069–4084. [Google Scholar] [CrossRef]
  36. Abdelsayed, E.M.; Medhat, D.; Mandour, Y.M.; Hanafi, R.S.; Motaal, A.A. Niazimicin: A thiocarbamate glycoside from Moringa oleifera Lam. seeds with a novel neuroprotective activity. J. Food Biochem. 2021, e13992. [Google Scholar] [CrossRef] [PubMed]
  37. Huang, L.; Yuan, C.; Wang, Y. Bioactivity-Guided Identification of Anti-Adipogenic Isothiocyanates in the Moringa (Moringa oleifera) Seed and Investigation of the Structure-Activity Relationship. Molecules 2020, 25, 2504. [Google Scholar] [CrossRef]
  38. Maldini, M.; Maksoud, S.A.; Natella, F.; Montoro, P.; Petretto, G.L.; Foddai, M.; De Nicola, G.R.; Chessa, M.; Pintore, G. Moringa oleifera: Study of phenolics and glucosinolates by mass spectrometry. J. Mass Spectrom. JMS 2014, 49, 900–910. [Google Scholar] [CrossRef]
  39. Muhammad, A.A.; Pauzi, N.A.; Arulselvan, P.; Abas, F.; Fakurazi, S. In vitro wound healing potential and identification of bioactive compounds from Moringa oleifera Lam. BioMed Res. Int. 2013, 2013, 974580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Dou, Z.; Chen, C.; Fu, X. Bioaccessibility, antioxidant activity and modulation effect on gut microbiota of bioactive compounds from Moringa oleifera Lam. leaves during digestion and fermentation in vitro. Food Funct. 2019, 10, 5070–5079. [Google Scholar] [CrossRef]
  41. Vats, S.; Gupta, T. Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa oleifera Lam. from Rajasthan, India. Physiol. Mol. Biol. Plants Int. J. Funct. Plant Biol. 2017, 23, 239–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Barhoi, D.; Upadhaya, P.; Barbhuiya, S.N.; Giri, A.; Giri, S. Aqueous Extract of Moringa oleifera Exhibit Potential Anticancer Activity and can be Used as a Possible Cancer Therapeutic Agent: A Study Involving In Vitro and In Vivo Approach. J. Am. Coll. Nutr. 2021, 40, 70–85. [Google Scholar] [CrossRef]
  43. Faizi, S.; Sumbul, S.; Versiani, M.A.; Saleem, R.; Sana, A.; Siddiqui, H. GC/GCMS analysis of the petroleum ether and dichloromethane extracts of Moringa oleifera roots. Asian Pac. J. Trop. Biomed. 2014, 4, 650–654. [Google Scholar] [CrossRef] [Green Version]
  44. Abd Rani, N.Z.; Kumolosasi, E.; Jasamai, M.; Jamal, J.A.; Lam, K.W.; Husain, K. In vitro anti-allergic activity of Moringa oleifera Lam. extracts and their isolated compounds. BMC Complementary Altern. Med. 2019, 19, 361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Sreelatha, S.; Jeyachitra, A.; Padma, P.R. Antiproliferation and induction of apoptosis by Moringa oleifera leaf extract on human cancer cells. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2011, 49, 1270–1275. [Google Scholar] [CrossRef]
  46. Karim, N.A.; Ibrahim, M.D.; Kntayya, S.B.; Rukayadi, Y.; Hamid, H.A.; Razis, A.F. Moringa oleifera Lam: Targeting Chemoprevention. Asian Pac. J. Cancer Prev. APJCP 2016, 17, 3675–3686. [Google Scholar]
  47. Khan, F.; Pandey, P.; Ahmad, V.; Upadhyay, T.K. Moringa oleifera methanolic leaves extract induces apoptosis and G0/G1 cell cycle arrest via downregulation of Hedgehog Signaling Pathway in human prostate PC-3 cancer cells. J. Food Biochem. 2020, 44, e13338. [Google Scholar] [CrossRef]
  48. Luetragoon, T.; Pankla Sranujit, R.; Noysang, C.; Thongsri, Y.; Potup, P.; Suphrom, N.; Nuengchamnong, N.; Usuwanthim, K. Anti-Cancer Effect of 3-Hydroxy-β-Ionone Identified from Moringa oleifera Lam. Leaf on Human Squamous Cell Carcinoma 15 Cell Line. Molecules 2020, 25, 3563. [Google Scholar] [CrossRef]
  49. Tiloke, C.; Phulukdaree, A.; Gengan, R.M.; Chuturgoon, A.A. Moringa oleifera Aqueous Leaf Extract Induces Cell-Cycle Arrest and Apoptosis in Human Liver Hepatocellular Carcinoma Cells. Nutr. Cancer 2019, 71, 1165–1174. [Google Scholar] [CrossRef] [PubMed]
  50. Caicedo-Lopez, L.H.; Cuellar-Nuñez, M.L.; Luzardo-Ocampo, I.; Campos-Vega, R.; Lóarca-Piña, G. Colonic metabolites from digested Moringa oleifera leaves induced HT-29 cell death via apoptosis, necrosis, and autophagy. Int. J. Food Sci. Nutr. 2021, 72, 485–498. [Google Scholar] [CrossRef] [PubMed]
  51. Xie, J.; Peng, L.J.; Yang, M.R.; Jiang, W.W.; Mao, J.Y.; Shi, C.Y.; Tian, Y.; Sheng, J. Alkaloid Extract of Moringa oleifera Lam. Exerts Antitumor Activity in Human Non-Small-Cell Lung Cancer via Modulation of the JAK2/STAT3 Signaling Pathway. Evid. -Based Complementary Altern. Med. Ecam 2021, 2021, 5591687. [Google Scholar] [CrossRef] [PubMed]
  52. Do, B.H.; Nguyen, T.P.T.; Ho, N.Q.C.; Le, T.L.; Hoang, N.S.; Doan, C.C. Mitochondria-mediated Caspase-dependent and Caspase-independent apoptosis induced by aqueous extract from Moringa oleifera leaves in human melanoma cells. Mol. Biol. Rep. 2020, 47, 3675–3689. [Google Scholar] [CrossRef]
  53. Abd-Rabou, A.A.; KhM, A.Z.; Kishta, M.S.; Shalby, A.B.; Ezzo, M.I. Nano-Micelle of Moringa oleifera Seed Oil Triggers Mitochondrial Cancer Cell Apoptosis. Asian Pac. J. Cancer Prev. APJCP 2016, 17, 49294–49933. [Google Scholar] [CrossRef]
  54. Potestà, M.; Minutolo, A.; Gismondi, A.; Canuti, L.; Kenzo, M.; Roglia, V.; Macchi, F.; Grelli, S.; Canini, A.; Colizzi, V.; et al. Cytotoxic and apoptotic effects of different extracts of Moringa oleifera Lam on lymphoid and monocytoid cells. Exp. Ther. Med. 2019, 18, 5–17. [Google Scholar] [CrossRef] [Green Version]
  55. Potestà, M.; Roglia, V.; Fanelli, M.; Pietrobono, E.; Gismondi, A.; Vumbaca, S.; Nguedia Tsangueu, R.G.; Canini, A.; Colizzi, V.; Grelli, S.; et al. Effect of microvesicles from Moringa oleifera containing miRNA on proliferation and apoptosis in tumor cell lines. Cell Death Discov. 2020, 6, 43. [Google Scholar] [CrossRef]
  56. Adebayo, I.A.; Arsad, H.; Samian, M.R. Antiproliferative effect on breast cancer (MCF7) of Moringa oleifera seed extracts. Afr. J. Tradit. Complementary Altern. Med. AJTCAM 2017, 14, 282–287. [Google Scholar] [CrossRef]
  57. Elsayed, E.A.; Sharaf-Eldin, M.A.; Wadaan, M. In vitro Evaluation of Cytotoxic Activities of Essential Oil from Moringa oleifera Seeds on HeLa, HepG2, MCF-7, CACO-2 and L929 Cell Lines. Asian Pac. J. Cancer Prev. APJCP 2015, 16, 4671–4675. [Google Scholar] [CrossRef] [Green Version]
  58. Patriota, L.L.S.; Ramos, D.B.M.; Dos Santos, A.; Silva, Y.A.; Gama, E.S.M.; Torres, D.J.L.; Procópio, T.F.; de Oliveira, A.M.; Coelho, L.; Pontual, E.V.; et al. Antitumor activity of Moringa oleifera (drumstick tree) flower trypsin inhibitor (MoFTI) in sarcoma 180-bearing mice. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2020, 145, 111691. [Google Scholar] [CrossRef]
  59. Al-Asmari, A.K.; Albalawi, S.M.; Athar, M.T.; Khan, A.Q.; Al-Shahrani, H.; Islam, M. Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines. PLoS ONE 2015, 10, e0135814. [Google Scholar] [CrossRef] [PubMed]
  60. Vasanth, K.; Ilango, K.; MohanKumar, R.; Agrawal, A.; Dubey, G.P. Anticancer activity of Moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction. Colloids Surf. B Biointerfaces 2014, 117, 354–359. [Google Scholar] [CrossRef] [PubMed]
  61. Siddiqui, S.; Upadhyay, S.; Ahmad, I.; Hussain, A.; Ahamed, M. Cytotoxicity of Moringa oleifera fruits on human liver cancer and molecular docking analysis of bioactive constituents against caspase-3 enzyme. J. Food Biochem. 2021, 45, e13720. [Google Scholar] [CrossRef]
  62. Bianchini, F.; Vainio, H. Isothiocyanates in cancer prevention. Drug Metab. Rev. 2004, 36, 655–667. [Google Scholar] [CrossRef]
  63. Romeo, L.; Iori, R.; Rollin, P.; Bramanti, P.; Mazzon, E. Isothiocyanates: An Overview of Their Antimicrobial Activity against Human Infections. Molecules 2018, 23, 624. [Google Scholar] [CrossRef] [Green Version]
  64. Fimognari, C.; Turrini, E.; Ferruzzi, L.; Lenzi, M.; Hrelia, P. Natural isothiocyanates: Genotoxic potential versus chemoprevention. Mutat. Res. 2012, 750, 107–131. [Google Scholar] [CrossRef]
  65. Dufour, V.; Stahl, M.; Baysse, C. The antibacterial properties of isothiocyanates. Microbiology 2015, 161, 229–243. [Google Scholar] [CrossRef] [Green Version]
  66. Burčul, F.; Generalić Mekinić, I.; Radan, M.; Rollin, P.; Blažević, I. Isothiocyanates: Cholinesterase inhibiting, antioxidant, and anti-inflammatory activity. J. Enzym. Inhib. Med. Chem. 2018, 33, 577–582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Soundararajan, P.; Kim, J.S. Anti-Carcinogenic Glucosinolates in Cruciferous Vegetables and Their Antagonistic Effects on Prevention of Cancers. Molecules 2018, 23, 2983. [Google Scholar] [CrossRef] [Green Version]
  68. Senthilkumar, A.; Karuvantevida, N.; Rastrelli, L.; Kurup, S.S.; Cheruth, A.J. Traditional Uses, Pharmacological Efficacy, and Phytochemistry of Moringa peregrina (Forssk.) Fiori.—A Review. Front. Pharmacol. 2018, 9, 465. [Google Scholar] [CrossRef] [Green Version]
  69. Palliyaguru, D.L.; Yuan, J.M.; Kensler, T.W.; Fahey, J.W. Isothiocyanates: Translating the Power of Plants to People. Mol. Nutr. Food Res. 2018, 62, e1700965. [Google Scholar] [CrossRef]
  70. Zhang, Q.C.; Pan, Z.H.; Liu, B.N.; Meng, Z.W.; Wu, X.; Zhou, Q.H.; Xu, K. Benzyl isothiocyanate induces protective autophagy in human lung cancer cells through an endoplasmic reticulum stress-mediated mechanism. Acta Pharmacol. Sin. 2017, 38, 539–550. [Google Scholar] [CrossRef] [PubMed]
  71. Kołodziejski, D.; Koss-Mikołajczyk, I.; Abdin, A.Y.; Jacob, C.; Bartoszek, A. Chemical Aspects of Biological Activity of Isothiocyanates and Indoles, the Products of Glucosinolate Decomposition. Curr. Pharm. Des. 2019, 25, 1717–1728. [Google Scholar] [CrossRef] [PubMed]
  72. Waterman, C.; Cheng, D.M.; Rojas-Silva, P.; Poulev, A.; Dreifus, J.; Lila, M.A.; Raskin, I. Stable, water extractable isothiocyanates from Moringa oleifera leaves attenuate inflammation in vitro. Phytochemistry 2014, 103, 114–122. [Google Scholar] [CrossRef] [Green Version]
  73. Tian, S.; Liu, X.; Lei, P.; Zhang, X.; Shan, Y. Microbiota: A mediator to transform glucosinolate precursors in cruciferous vegetables to the active isothiocyanates. J. Sci. Food Agric. 2018, 98, 1255–1260. [Google Scholar] [CrossRef]
  74. Jaja-Chimedza, A.; Graf, B.L.; Simmler, C.; Kim, Y.; Kuhn, P.; Pauli, G.F.; Raskin, I. Biochemical characterization and anti-inflammatory properties of an isothiocyanate-enriched moringa (Moringa oleifera) seed extract. PLoS ONE 2017, 12, e0182658. [Google Scholar] [CrossRef] [Green Version]
  75. Brunelli, D.; Tavecchio, M.; Falcioni, C.; Frapolli, R.; Erba, E.; Iori, R.; Rollin, P.; Barillari, J.; Manzotti, C.; Morazzoni, P.; et al. The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochem. Pharmacol. 2010, 79, 1141–1148. [Google Scholar] [CrossRef] [Green Version]
  76. Li, S.; Li, W.; Wu, R.; Yin, R.; Sargsyan, D.; Raskin, I.; Kong, A.N. Epigenome and transcriptome study of moringa isothiocyanate in mouse kidney mesangial cells induced by high glucose, a potential model for diabetic-induced nephropathy. AAPS J. 2019, 22, 8. [Google Scholar] [CrossRef]
  77. Waterman, C.; Graham, J.L.; Arnold, C.D.; Stanhope, K.L.; Tong, J.H.; Jaja-Chimedza, A.; Havel, P.J. Moringa Isothiocyanate-rich Seed Extract Delays the Onset of Diabetes in UC Davis Type-2 Diabetes Mellitus Rats. Sci. Rep. 2020, 10, 8861. [Google Scholar] [CrossRef] [PubMed]
  78. Romeo, L.; Diomede, F.; Gugliandolo, A.; Scionti, D.; Lo Giudice, F.; Lanza Cariccio, V.; Iori, R.; Bramanti, P.; Trubiani, O.; Mazzon, E. Moringin Induces Neural Differentiation in the Stem Cell of the Human Periodontal Ligament. Sci. Rep. 2018, 8, 9153. [Google Scholar] [CrossRef]
  79. Müller, C.; van Loon, J.; Ruschioni, S.; De Nicola, G.R.; Olsen, C.E.; Iori, R.; Agerbirk, N. Taste detection of the non-volatile isothiocyanate moringin results in deterrence to glucosinolate-adapted insect larvae. Phytochemistry 2015, 118, 139–148. [Google Scholar] [CrossRef] [PubMed]
  80. Chiricosta, L.; Gugliandolo, A.; Diomede, F.; Pizzicannella, J.; Trubiani, O.; Iori, R.; Tardiolo, G.; Guarnieri, S.; Bramanti, P.; Mazzon, E. Moringin Pretreatment Inhibits the Expression of Genes Involved in Mitophagy in the Stem Cell of the Human Periodontal Ligament. Molecules 2019, 24, 3217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  81. Giacoppo, S.; Iori, R.; Bramanti, P.; Mazzon, E. Topical moringin-cream relieves neuropathic pain by suppression of inflammatory pathway and voltage-gated ion channels in murine model of multiple sclerosis. Mol. Pain 2017, 13, 1744806917724318. [Google Scholar] [CrossRef]
  82. Giacoppo, S.; Rajan, T.S.; Iori, R.; Rollin, P.; Bramanti, P.; Mazzon, E. The α-cyclodextrin complex of the Moringa isothiocyanate suppresses lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells through Akt and p38 inhibition. Inflamm. Res. 2017, 66, 487–503. [Google Scholar] [CrossRef]
  83. Romeo, L.; Lanza Cariccio, V.; Iori, R.; Rollin, P.; Bramanti, P.; Mazzon, E. The α-Cyclodextrin/Moringin Complex: A New Promising Antimicrobial Agent against Staphylococcus aureus. Molecules 2018, 23, 2097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Galuppo, M.; Giacoppo, S.; Iori, R.; De Nicola, G.R.; Bramanti, P.; Mazzon, E. Administration of 4-(α-L-rhamnosyloxy)-benzyl isothiocyanate delays disease phenotype in SOD1(G93A) rats: A transgenic model of amyotrophic lateral sclerosis. BioMed Res. Int. 2015, 2015, 259417. [Google Scholar] [CrossRef] [Green Version]
  85. Cirmi, S.; Ferlazzo, N.; Gugliandolo, A.; Musumeci, L.; Mazzon, E.; Bramanti, A.; Navarra, M. Moringin from Moringa oleifera Seeds Inhibits Growth, Arrests Cell-Cycle, and Induces Apoptosis of SH-SY5Y Human Neuroblastoma Cells through the Modulation of NF-κB and Apoptotic Related Factors. Int. J. Mol. Sci. 2019, 20, 1930. [Google Scholar] [CrossRef] [Green Version]
  86. Jaafaru, M.S.; Nordin, N.; Shaari, K.; Rosli, R.; Abdull Razis, A.F. Isothiocyanate from Moringa oleifera seeds mitigates hydrogen peroxide-induced cytotoxicity and preserved morphological features of human neuronal cells. PLoS ONE 2018, 13, e0196403. [Google Scholar] [CrossRef] [Green Version]
  87. Rajan, T.S.; De Nicola, G.R.; Iori, R.; Rollin, P.; Bramanti, P.; Mazzon, E. Anticancer activity of glucomoringin isothiocyanate in human malignant astrocytoma cells. Fitoterapia 2016, 110, 1–7. [Google Scholar] [CrossRef]
  88. Michl, C.; Vivarelli, F.; Weigl, J.; De Nicola, G.R.; Canistro, D.; Paolini, M.; Iori, R.; Rascle, A. The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling. PLoS ONE 2016, 11, e0157430. [Google Scholar] [CrossRef]
  89. Waterman, C.; Rojas-Silva, P.; Tumer, T.B.; Kuhn, P.; Richard, A.J.; Wicks, S.; Stephens, J.M.; Wang, Z.; Mynatt, R.; Cefalu, W.; et al. Isothiocyanate-rich Moringa oleifera extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice. Mol. Nutr. Food Res. 2015, 59, 1013–1024. [Google Scholar] [CrossRef] [Green Version]
  90. Fahey, J.W.; Wade, K.L.; Stephenson, K.K.; Shi, Y.; Liu, H.; Panjwani, A.A.; Warrick, C.R.; Olson, M.E. A Strategy to Deliver Precise Oral Doses of the Glucosinolates or Isothiocyanates from Moringa oleifera Leaves for Use in Clinical Studies. Nutrients 2019, 11, 1547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  91. Kim, Y.; Jaja-Chimedza, A.; Merrill, D.; Mendes, O.; Raskin, I. A 14-day repeated-dose oral toxicological evaluation of an isothiocyanate-enriched hydro-alcoholic extract from Moringa oleifera Lam. seeds in rats. Toxicol. Rep. 2018, 5, 418–426. [Google Scholar] [CrossRef] [PubMed]
  92. Maiyo, F.C.; Moodley, R.; Singh, M. Cytotoxicity, Antioxidant and Apoptosis Studies of Quercetin-3-O Glucoside and 4-(β-D-Glucopyranosyl-1→4-α-L-Rhamnopyranosyloxy)-Benzyl Isothiocyanate from Moringa oleifera. Anti-Cancer Agents Med. Chem. 2016, 16, 648–656. [Google Scholar] [CrossRef]
  93. O’Shea, J.J.; Schwartz, D.M.; Villarino, A.V.; Gadina, M.; McInnes, I.B.; Laurence, A. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu. Rev. Med. 2015, 66, 311–328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Pedram, M.; Vafaie, M.; Fekri, K.; Haghi, S.; Rashidi, I.; Pirooti, C. Cerebellar neuroblastoma in 2.5 years old child. Iran. J. Cancer Prev. 2013, 6, 174–176. [Google Scholar] [PubMed]
  95. Mei, H.; Wang, Y.; Lin, Z.; Tong, Q. The mTOR signaling pathway in pediatric neuroblastoma. Pediatric Hematol. Oncol. 2013, 30, 605–615. [Google Scholar] [CrossRef]
  96. Sui, X.; Kong, N.; Ye, L.; Han, W.; Zhou, J.; Zhang, Q.; He, C.; Pan, H. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014, 344, 174–179. [Google Scholar] [CrossRef] [PubMed]
  97. Giacoppo, S.; Iori, R.; Rollin, P.; Bramanti, P.; Mazzon, E. Moringa isothiocyanate complexed with α-cyclodextrin: A new perspective in neuroblastoma treatment. BMC Complementary Altern. Med. 2017, 17, 362. [Google Scholar] [CrossRef] [Green Version]
  98. Hirtz, A.; Rech, F.; Dubois-Pot-Schneider, H.; Dumond, H. Astrocytoma: A Hormone-Sensitive Tumor? Int. J. Mol. Sci. 2020, 21, 9114. [Google Scholar] [CrossRef]
  99. Carneiro, B.A.; El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 2020, 17, 395–417. [Google Scholar] [CrossRef]
  100. Antonini, E.; Iori, R.; Ninfali, P.; Scarpa, E.S. A Combination of Moringin and Avenanthramide 2f Inhibits the Proliferation of Hep3B Liver Cancer Cells Inducing Intrinsic and Extrinsic Apoptosis. Nutr. Cancer 2018, 70, 1159–1165. [Google Scholar] [CrossRef]
  101. Goldstein, J.; Roth, E.; Roberts, N.; Zwick, R.; Lin, S.; Fletcher, S.; Tadeu, A.; Wu, C.; Beck, A.; Zeiss, C.; et al. Loss of endogenous Nfatc1 reduces the rate of DMBA/TPA-induced skin tumorigenesis. Mol. Biol. Cell 2015, 26, 3606–3614. [Google Scholar] [CrossRef]
  102. Wang, C.; Wu, R.; Sargsyan, D.; Zheng, M.; Li, S.; Yin, R.; Su, S.; Raskin, I.; Kong, A.N. CpG methyl-seq and RNA-seq epigenomic and transcriptomic studies on the preventive effects of Moringa isothiocyanate in mouse epidermal JB6 cells induced by the tumor promoter TPA. J. Nutr. Biochem. 2019, 68, 69–78. [Google Scholar] [CrossRef]
  103. Lu, Y.; Maria Vos, R.D.; Zhang, Y.; Zhang, M.; Liu, Y.; Fu, C.; Liu, S.Q.; Huang, D. The degradation kinetics and mechanism of moringin in aqueous solution and the cytotoxicity of degraded products. Food Chem. 2021, 364, 130424. [Google Scholar] [CrossRef] [PubMed]
  104. Opal, S.M. Endotoxins and other sepsis triggers. Contrib. Nephrol. 2010, 167, 14–24. [Google Scholar] [CrossRef] [PubMed]
  105. Sailaja, B.S.; Aita, R.; Maledatu, S.; Ribnicky, D.; Verzi, M.P.; Raskin, I. Moringa isothiocyanate-1 regulates Nrf2 and NF-κB pathway in response to LPS-driven sepsis and inflammation. PLoS ONE 2021, 16, e0248691. [Google Scholar] [CrossRef]
  106. Kim, Y.; Wu, A.G.; Jaja-Chimedza, A.; Graf, B.L.; Waterman, C.; Verzi, M.P.; Raskin, I. Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice. PLoS ONE 2017, 12, e0184709. [Google Scholar] [CrossRef]
  107. Boroujerdi, A.; Welser-Alves, J.V.; Milner, R. Extensive vascular remodeling in the spinal cord of pre-symptomatic experimental autoimmune encephalomyelitis mice; increased vessel expression of fibronectin and the α5β1 integrin. Exp. Neurol. 2013, 250, 43–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Galuppo, M.; Giacoppo, S.; De Nicola, G.R.; Iori, R.; Navarra, M.; Lombardo, G.E.; Bramanti, P.; Mazzon, E. Antiinflammatory activity of glucomoringin isothiocyanate in a mouse model of experimental autoimmune encephalomyelitis. Fitoterapia 2014, 95, 160–174. [Google Scholar] [CrossRef]
Molecules 26 07512 g001 550
Figure 1. Schematics of Moringa oleifera representative body parts.
Figure 1. Schematics of Moringa oleifera representative body parts.
Molecules 26 07512 g001
Molecules 26 07512 g002 550
Figure 2. Chemical structures of moringa isothiocyanates.
Figure 2. Chemical structures of moringa isothiocyanates.
Molecules 26 07512 g002
Molecules 26 07512 g003 550
Figure 3. Proposed molecular target of MIC-1 as an anti-cancer agent. This figure is some of the signaling pathways that MIC-1 participates in cancer cells, as well as the proteins and genes regulated by these signaling pathways. Green boxes represent the downregulated genes or proteins, and red boxes represent the upregulated genes or proteins. COX-2: Cyclooxygenase-2; iNOS: Inducible nitric oxide synthase; IL-6: Interleukin-6; IL-8: Interleukin-8; JNK: c-Jun NH2-terminal kinase; p38: p38 Mitogen-activated protein kinase; MKP-1: Mitogen-activated protein kinase phosphatase-1; PP2A: Protein phosphatase 2A; Erk1/2: Extracelluar signal-regulated kinase 1/2; p-PI3K: Phosphorylated phosphatidylinositol 3-kinase; p-AKT: Phosphorylated protein kinase B; p-mTOR: Phosphorylated mammalian target of rapamycin; Cis: Cytokine-inducible SH2-containing protein; Osm: Oncostatin M; c-Myc: MYC proto-oncogene; Bcl-2: B-cell lymphoma 2; Bax: BCL2-associated X protein; p21: Cyclin-dependent kinase inhibitor 1; p53: Tumor suppressor p53; Nrf2: Nuclear factor erythroid-2-related factor 2; CK2: Casein kinase 2; GST: Glutathione S-transferase; GCLC: glutamate-cysteine ligase catalytic subunit; SOD1: Superoxide dismutase 1; SOD2: Superoxide dismutase 2; HO-1: Heme oxygenase 1; STAT: Signal transducer and activator of transcription.
Figure 3. Proposed molecular target of MIC-1 as an anti-cancer agent. This figure is some of the signaling pathways that MIC-1 participates in cancer cells, as well as the proteins and genes regulated by these signaling pathways. Green boxes represent the downregulated genes or proteins, and red boxes represent the upregulated genes or proteins. COX-2: Cyclooxygenase-2; iNOS: Inducible nitric oxide synthase; IL-6: Interleukin-6; IL-8: Interleukin-8; JNK: c-Jun NH2-terminal kinase; p38: p38 Mitogen-activated protein kinase; MKP-1: Mitogen-activated protein kinase phosphatase-1; PP2A: Protein phosphatase 2A; Erk1/2: Extracelluar signal-regulated kinase 1/2; p-PI3K: Phosphorylated phosphatidylinositol 3-kinase; p-AKT: Phosphorylated protein kinase B; p-mTOR: Phosphorylated mammalian target of rapamycin; Cis: Cytokine-inducible SH2-containing protein; Osm: Oncostatin M; c-Myc: MYC proto-oncogene; Bcl-2: B-cell lymphoma 2; Bax: BCL2-associated X protein; p21: Cyclin-dependent kinase inhibitor 1; p53: Tumor suppressor p53; Nrf2: Nuclear factor erythroid-2-related factor 2; CK2: Casein kinase 2; GST: Glutathione S-transferase; GCLC: glutamate-cysteine ligase catalytic subunit; SOD1: Superoxide dismutase 1; SOD2: Superoxide dismutase 2; HO-1: Heme oxygenase 1; STAT: Signal transducer and activator of transcription.
Molecules 26 07512 g003
Table
Table 1. Major bioactive compound in different body parts of M. oleifera.
Table 1. Major bioactive compound in different body parts of M. oleifera.
LocationBioactive CompoundsReference
Seedglycosidic benzylamines; niazimicin; isothiocyanates; phenolics; glucosinolates[35,36,37,38]
Leafphytol; flavonoids; phenolics; β-carotene; lycopene; vicenin-2; quinic acid; octadecanoic acid; hexadecanoic acid (palmitic acid); α-tocopherol (vitamin-E); ɣ-sitosterol[32,39,40,41,42]
Flowerβ-sitosterol; flavonoids; anthocyanin[41]
Rootnasimizinol; oleic acid; N-benzyl-N-(7-cyanato heptanamide; N-benzyl-N-(1-chlorononyl) amide; bis [3-benzyl prop-2-ene]-1-one; N, N-dibenzyl-2-ene pent-1,5-diamide[43]
Shell3,5,6-trihydroxy-2-(2,3,4,5,6-pentahydroxyphenyl)-4H-chromen-4-one; β-sitosterol-3-O-glucoside; 2,3,4-trihydroxybenzaldehyde; stigmasterol[44]
Barkepiglobulol; flavonoids; anthocyanin[41]
Table
Table 2. The extraction methods and functions of MIC-1.
Table 2. The extraction methods and functions of MIC-1.
LocationFunctionExtraction MethodReference
Seedanti-inflammation; anti-diabetic; counteracting ulcerative colitisJaja-Chimedza et al.[25,74,76,77]
Seedanti-cancer; counteracting neurodegeneration; anti-oxidation; counteracting neuropathic pain; anti-inflammation; antibiotics; counteracting amyotrophic lateral sclerosisBrunelli et al.[75,78,79,80,81,82,83,84,85,86,87,88]
Leafanti-inflammation; anti-obesity, anti-diabeticWaterman et al.[72,89]
Leafanti-inflammationFahey et al.[90]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Wu, Y.-Y.; Xu, Y.-M.; Lau, A.T.Y. Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate. Molecules 2021, 26, 7512. https://doi.org/10.3390/molecules26247512

AMA Style

Wu Y-Y, Xu Y-M, Lau ATY. Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate. Molecules. 2021; 26(24):7512. https://doi.org/10.3390/molecules26247512

Chicago/Turabian Style

Wu, Yu-Yao, Yan-Ming Xu, and Andy T. Y. Lau. 2021. "Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate" Molecules 26, no. 24: 7512. https://doi.org/10.3390/molecules26247512

APA Style

Wu, Y. -Y., Xu, Y. -M., & Lau, A. T. Y. (2021). Anti-Cancer and Medicinal Potentials of Moringa Isothiocyanate. Molecules, 26(24), 7512. https://doi.org/10.3390/molecules26247512

Article Metrics

Back to TopTop